Frequently asked questions Kye, living life with Dravet syndrome To help you learn more about FINTEPLA, see below for answers to commonly asked questions. When you’re ready, talk to your healthcare provider to decide if FINTEPLA is right for you or your loved one. Frequently Asked Questions What is FINTEPLA? FINTEPLA is a prescription medicine used to treat the seizures associated with Dravet syndrome and LGS in patients 2 years of age and older. How is FINTEPLA taken? FINTEPLA is a cherry-flavored liquid that is taken by mouth (administered orally) and can be taken with or without food. Read the Instructions for Use at the end of the FINTEPLA Medication Guide for information on the right way to take FINTEPLA. How can my loved one get on FINTEPLA? FINTEPLA is available only through the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS). In the past, some adults who took fenfluramine, the active ingredient in FINTEPLA, developed problems with their heart valves that caused valvular heart disease or high blood pressure in the arteries of their lungs. The FINTEPLA REMS is designed to help manage these potential safety concerns.Before your loved one receives FINTEPLA, your healthcare provider will check their heart valves and lung artery pressure with a test called an echocardiogram (echo), which is an ultrasound picture of the heart. After enrolling in the FINTEPLA REMS and reviewing your loved one’s echo results, you and your healthcare provider will decide whether to begin FINTEPLA. Did patients in the FINTEPLA clinical studies develop problems with the heart valves or high blood pressure in the arteries of the lungs? None of the 603 patients who took FINTEPLA during the clinical studies developed problems with their heart valves that caused valvular heart disease or high blood pressure in the arteries of the lungs, including patients treated for up to 3 years. However, the FINTEPLA REMS can help to identify any problems before symptoms develop. Is financial assistance available for FINTEPLA? UCB is committed to making FINTEPLA affordable and accessible for all patients and sponsors several financial assistance programs, including the ONWARD™ Copay Assistance Program and the ONWARD Support Program.For more information about these financial assistance programs, please call ONWARD at 1-888-964-3649. Can FINTEPLA be taken with other antiseizure medications? During clinical studies, patients were on their current treatment plans, including other antiseizure medicines or treatments, such as use of a vagal nerve stimulator or ketogenic diet, while taking FINTEPLA. If you have additional questions about taking other medicines with FINTEPLA, speak with your healthcare provider. Can FINTEPLA be taken with cannabidiol (CBD)? Yes. FINTEPLA can be taken with commercially available CBD. If you have additional questions, speak with your healthcare provider. Can FINTEPLA be taken while on a ketogenic diet? Yes. There are no restrictions for use of FINTEPLA while on a ketogenic diet. In fact, patients on a ketogenic diet were included in the FINTEPLA clinical trials. Remember to discuss with your healthcare provider all treatments you may be taking, including the ketogenic diet. Can FINTEPLA be taken with feeding tubes? Yes. FINTEPLA is compatible with feeding tubes. If you have additional questions, speak with your healthcare provider. What are the most common side effects of FINTEPLA? For patients with Dravet syndrome treated with FINTEPLA (0.7 mg/kg/day), the most common side effects include: decreased appetite; diarrhea; low energy; respiratory infection; decreased weight; fever; constipation; abnormal echocardiogram; sleepiness; problems with movement, balance, and walking; increased drooling; increased blood pressure; vomiting; falls; seizures that do not stop; weakness.For patients with LGS treated with FINTEPLA (0.7 mg/kg/day), the most common side effects include: diarrhea; tiredness; vomiting; sleepiness; decreased appetite.Some patients in the clinical studies experienced a decrease in appetite and weight. However, most patients with Dravet syndrome and approximately half of patients with LGS resumed expected weight gains during the open-label extension study. If you have additional questions, speak with your healthcare provider. Explore what FINTEPLA has to offerGet downloadable brochures for Dravet syndrome and LGS to see seizure reduction results, studies, and more—all in one place.Get resourcesAsk your questions in real timeTalk live with a FINTEPLA Clinical Nurse Educator, a registered nurse who is highly knowledgeable about FINTEPLA.Learn more Stay InformedInterested in receiving helpful information about FINTEPLA and Dravet syndrome or Lennox-Gastaut syndrome (LGS)?Register below to personally receive support resources, inspiring patient stories, educational content, and more.The fields marked with an asterisk (*) are mandatory. First Name Last Name Email Address I am interested in learning more about:*Please select one. Dravet syndrome Lennox-Gastaut syndrome (LGS) Which of the following best describes you?* I am caring for a child or an adult with Dravet syndrome I am a family member or friend of a child or adult with Dravet syndrome I am a healthcare professional seeking information on FINTEPLA I understand that by submitting my information, I will receive news and updates about UCB, Inc. and its products, clinical trials, research opportunities, programs, and other information that may be of interest to me. For more information on UCB’s Privacy Policy, visit https://www.ucb-usa.com/policy. Leave this field blank